Gerald A. Brunk - Jun 15, 2024 Form 4 Insider Report for enGene Holdings Inc. (ENGN)

Role: Director
Signature: /s/ Alex J. Nichols, as attorney-in-fact for the Reporting Person
Stock symbol: ENGN
Transactions as of: Jun 15, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/18/2024, 04:04 PM
Previous filing: Feb 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENGN	Stock Option (Right to Buy)	Award	$0	+20K		$0.00	20K	Jun 15, 2024	Common Shares	20K	$9.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders.
F2	These options are held of record by Mr. Brunk for the benefit of Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"). Mr. Brunk expressly disclaims beneficial ownership of these securities.

Content

This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders.

These options are held of record by Mr. Brunk for the benefit of Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"). Mr. Brunk expressly disclaims beneficial ownership of these securities.